Associate Professor

Colm Keane

Email: 
Phone: 
+61 7 344 37912

Background

Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.

Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.

Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.

The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.

Availability

Associate Professor Colm Keane is:
Available for supervision

Qualifications

  • Masters (Coursework) of Business Administration, Griffith University
  • Doctor of Philosophy, Griffith University

Research interests

  • Tumour Immunology

  • DLBCL

  • Primary CNS Lymphoma

  • Hodgkin Lymphoma

  • Viral Associated Lymphomas

Search Professor Colm Keane’s works on UQ eSpace

129 works between 2004 and 2025
All (129) Journal Article (69) Book Chapter (1) Conference Publication (59)

41 - 60 of 129 works

2023

Journal Article

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Agrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

2023

Journal Article

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew and Hawkes, Eliza A. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia, 37 (5), 1092-1102. doi: 10.1038/s41375-023-01863-7

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

2022

Journal Article

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Baggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M. and Hawkes, Eliza A. (2022). Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leukemia & Lymphoma, 64 (3), 621-627. doi: 10.1080/10428194.2022.2157676

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

2022

Conference Publication

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166846

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

2022

Conference Publication

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166670

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

2022

Journal Article

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Lymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

2022

Conference Publication

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890800.36906.bb

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

2022

Conference Publication

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890812.66186.e8

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

2022

Conference Publication

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

2022

Journal Article

Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Keane, Colm, Hamad, Nada, Barraclough, Allison, Lee, Yoo Y., Talaulikar, Dipti, Ku, Matthew, Wight, Joel, Tatarczuch, Maciej, Swain, Fiona and Gregory, Gareth P. (2022). Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (9), 1624-1632. doi: 10.1111/imj.15658

Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

2022

Journal Article

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

Gandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

2022

Conference Publication

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

2022

Conference Publication

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study

Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Inna, Tzoran, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study

2021

Conference Publication

The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma

Gunawardana, Jay, Sabdia, Muhammed B., Bednarska, Karolina, Law, Soi C., Brosda, Sandra, Tsang, Hennes, De Long, Lilia Merida, Zaharia, Andreea, Lee, Justina, Jude, Emily, Hawkes, Eliza, Nath, Karthik, Gould, Clare, Burgess, Melinda Lea, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Talaulikar, Dipti, Jain, Sanjiv, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher (2021). The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-145840

The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma

2021

Journal Article

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

Shanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

2021

Journal Article

Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis

Keane, Colm, Coalter, Matthew and Martin-Loeches, Ignacio (2021). Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis. Frontiers in Medicine, 8 711397, 1-12. doi: 10.3389/fmed.2021.711397

Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis

2021

Journal Article

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Proctor, Martina, Gonzalez Cruz, Jazmina L., Daignault-Mill, Sheena M., Veitch, Margaret, Zeng, Bijun, Ehmann, Anna, Sabdia, Muhammed, Snell, Cameron, Keane, Colm, Dolcetti, Riccardo, Haass, Nikolas K., Wells, James W. and Gabrielli, Brian (2021). Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 13 (15) 3733, 1-19. doi: 10.3390/cancers13153733

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

2021

Conference Publication

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Manos, Kate, Khor, Richard, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew M., Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Hawkes, Eliza (2021). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

2021

Journal Article

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Nath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

2021

Journal Article

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

Law, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

Current funding

  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2027
    An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas -- 2: TREBL-2 (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2026
    Investigation of Immune evasion in relapsed lymphoma (RADD Trial) (Victorian Cancer Agency Translational Research Project administered by La Trobe University)
    Olivia Newton-John Cancer Research Institute
    Open grant
  • 2021 - 2025
    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
    NHMRC MRFF Investigator Grant
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2021 - 2024
    ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
    Australasian Leukaemia & Lymphoma Group
    Open grant
  • 2021 - 2025
    Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University)
    La Trobe University
    Open grant
  • 2020 - 2023
    Novel immune based approaches to improve survival for patients with Primary Central Nervous Lymphoma
    Queensland Advancing Clinical Research Fellowship
    Open grant
  • 2019 - 2020
    Investigation of the key immuno-genetic drivers of Primary Central Nervous System Lymphoma that occurs in patients with HIV infection
    Cancer Australia
    Open grant
  • 2017 - 2020
    Investigation of unique immune microenvironment of Primary CNS Lymphoma
    NHMRC Early Career Fellowships
    Open grant
  • 2017 - 2019
    The prognostic utility of the tumour microenvironment in Non-Hodgkin's Lymphoma
    Celgene Pty Ltd
    Open grant
  • 2016 - 2017
    Does lymphoma avoid immune destruction by inducing T-cell tolerance?
    Cancer Council Queensland
    Open grant
  • 2015 - 2018
    A correlative laboratory study of primary CNS lymphoma
    Research Donation Generic
    Open grant
  • 2015 - 2018
    Net tumoral immunity and its impact on outcome in lymphoma
    The Leukaemia Foundation of Australia Limited
    Open grant

Availability

Associate Professor Colm Keane is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au